Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Latest News on RLMD

Apr 14, 2025, 8:41 AM EDT - 5 days ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 14, 2025, 7:30 AM EDT - 5 days ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 23 days ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 23 days ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 24 days ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 25 days ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 2 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 4 months ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 4 months ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 4 months ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 4 months ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 4 months ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 5 months ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 5 months ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 5 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 5 months ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 5 months ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 9 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 9 months ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 9 months ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 9 months ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 9 months ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 9 months ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 9 months ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 9 months ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 9 months ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 9 months ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 9 months ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 10 months ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Jul 12, 2024, 6:45 PM EDT - 10 months ago

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

Jul 11, 2024, 2:15 PM EDT - 10 months ago

Relmada Therapeutics Inc Under Scrutiny By The Schall Law Firm For Potential Securities Breaches Urging Affected Investors To Initiate Conversation

Jul 10, 2024, 2:30 PM EDT - 10 months ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Dialogue

Jul 9, 2024, 3:00 PM EDT - 10 months ago

Relmada Therapeutics Inc Is Being Probed By The Schall Law Firm For Potential Securities Breaches And Affected Investors Are Encouraged To Set Up Communication

Jul 8, 2024, 1:45 PM EDT - 10 months ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Communication

Jul 7, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Begins Probe Into Relmada Therapeutics Inc For Suspected Securities Violations And Promotes Investors With Losses To Get In Touch

Jul 6, 2024, 11:00 AM EDT - 10 months ago

Investigation Into Possible Securities Infringements By Relmada Therapeutics Inc Is Being Conducted By The Schall Law Firm And It Invites Affected Investors To Reach Out

Jul 5, 2024, 4:00 PM EDT - 10 months ago

The Schall Law Firm Initiates Examination Into Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Establish Contact

Jul 3, 2024, 12:30 PM EDT - 10 months ago

The Schall Law Firm Investigates Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Connect

Jul 2, 2024, 3:30 PM EDT - 10 months ago

The Schall Law Firm Probes Relmada Therapeutics Inc For Possible Securities Violations And Urges Affected Investors To Contact

Jun 28, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Infringements Of Securities Regulations And Encourages Investors Who Experienced Losses To Make Contact

Jun 26, 2024, 11:30 PM EDT - 10 months ago

The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Breaches Of Securities Laws And Urges Investors Who Sustained Losses To Reach Out

Jun 24, 2024, 4:45 PM EDT - 10 months ago

The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Securities Law Breaches And Urges Investors Who Incurred Losses To Reach Out

Jun 23, 2024, 11:00 AM EDT - 10 months ago

Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Being Investigated By The Schall Law Firm Investors Who Have Suffered Losses Are Encouraged To Connect With The Firm

Jun 22, 2024, 11:00 AM EDT - 10 months ago

Possible Breaches Of Securities Laws By Relmada Therapeutics Inc Are Being Probed By The Schall Law Firm Investors With Financial Losses Are Invited To Reach Out To The Firm

Jun 19, 2024, 4:05 PM EDT - 10 months ago

Potential Violations Of Securities Laws By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Investors Who Have Incurred Financial Losses Are Encouraged To Contact The Firm

Jun 18, 2024, 4:30 PM EDT - 10 months ago

The Schall Law Firm Is Probing Potential Securities Breaches By Relmada Therapeutics Inc Investors With Monetary Losses Are Urged To Reach Out To The Firm

Jun 18, 2024, 8:30 AM EDT - 10 months ago

Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry

Jun 17, 2024, 7:15 PM EDT - 10 months ago

Relmada Therapeutics Inc. (NASDAQ: RLMD) Under Investigation By Schall Law Firm For Potential Securities Violations. Investors Who Lost Money Encouraged To Contact The Firm

Jun 11, 2024, 7:45 PM EDT - 11 months ago

Market Cap	9.62M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	113,900
Avg Vol	1,019,270
Day's Range	N/A - N/A
Shares Out	33.19M
Stochastic %K	54%
Beta	0.41
Analysts	Hold
Price Target	$0.87